CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,692 enrolled
Drug / intervention
Arm 1 (ATP+Shock) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02923726
NCT02923726N/ACompleted
CompareCT.gov

Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP (APPRAISE ATP)

Boston Scientific Corporation·interventional·Posted Oct 5, 2016·Updated Oct 22, 2024

In Brief

A clinical study evaluating Arm 1 (ATP+Shock) and Arm 2 (shock only) for Sudden Cardiac Death. Completed, enrolled 2,692 participants across 134 sites in 8 countries.

Detailed Summary

The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for implantable cardioverter-defibrillator (ICD) therapy and programmed according to current guidance of higher rate cut-offs and therapy delays. The time to first all-cause shock will be tested in subjects with standard therapy (ATP and shocks) compared to subjects programmed to shock only to assess equivalency.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSudden Cardiac Death
CountriesAustria, Canada, Italy, Japan, South Korea, Spain, United Kingdom, United States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedOct 5, 2016
Enrollment StartSep 30, 2016
Primary CompletionJul 6, 2023
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 9.7 years ago

Interventions

Arm 1 (ATP+Shock)device

Subjects will be randomized and device programmed to the respective arm.

Arm 2 (shock only)device

Subjects will be randomized and device programmed to the respective arm.